Home Technology Here’s Why Salesforce (CRM) Stock Plunged 8.3% Today

Here’s Why Salesforce (CRM) Stock Plunged 8.3% Today

0
Here’s Why Salesforce (CRM) Stock Plunged 8.3% Today

[ad_1]

This story originally appeared on Zacks

Cloud-based software giant Salesforce CRM closed down over 8% on Wednesday after UBS analyst Karl Keirstead cut his rating and price target on the stock. Kierstead downgraded CRM to Neutral from Buy and lowered his PT on the shares to $265 from $315.

– Zacks

He argued that Salesforce’s sales growth may take a hit in 2022 because enough enterprise customers are reducing their spending. “[The potential decrease in growth] may outweigh the positive associated with the improving margin narrative.”

Shares of CRM have been under pressure since dropping 11% following its Q3 earnings report, while a general bearish attitude towards tech stocks have led to further market declines. CRM currently trades well below its all-time reached last November. Salesforce is a Zacks Rank #1 (Strong Buy), and its next earnings release is slated for the end of February.

Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
salesforce.com, inc. (CRM): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

[ad_2]

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here